Treatment of squamous cell carcinoma of the uterine cervix with radiation therapy alone: long-term survival, late complications, and incidence of second cancers
Treatment of squamous cell carcinoma of the uterine cervix with radiation therapy alone: long-term survival, late complications, and incidence of second cancers
复制标题
DOI：
10.1038/sj.bjc.6604005
复制
发表时间：
2007-10-16
影响因子：
8.8
通讯作者：
Takizawa, K.
中科院分区：
文献类型：
--
作者：
Ota, T.;Takeshima, N.;Takizawa, K.
本回顾性研究的目的是确定宫颈癌单纯放射治疗的生存率、晚期并发症的发生率和继发癌的发生率。1971年至1995年，1495例宫颈鳞状细胞癌（I-IV期）在我院接受了单独放射治疗。放射治疗包括高剂量率腔内近距离放射治疗和外照射放射治疗的组合。Ib、II和III/IVa期癌的累积5年生存率分别为93.5%、77.0%和60.3%，10年生存率分别为90.9%、74.5%和56.1%。Ib期、II期和III/IVa期癌的局部控制率分别为92.0%、79.4%和64.2%。82例（5.5%）患者发生III/IV级或V级（致死性）并发症。13例（0.87%）患者发生第二种癌症。第二种癌症最常见于直肠（5例）、结肠（3例）和子宫体（2例）。长期随访数据显示，我们的方法单独放射治疗局部晚期宫颈癌是有效的，晚期并发症和第二癌的发生率低。
The objective of this retrospective study was to determine the survival rate, incidence of late complications, and incidence of second cancers when radiation therapy alone is used for carcinoma of the uterine cervix. Between 1971 and 1995, 1495 patients with squamous cell carcinoma of the uterine cervix (stages I-IV) were treated with radiation therapy alone in our hospital. Radiation therapy consisted of a combination of high-dose-rate intracavitary brachytherapy and external beam radiotherapy. The cumulative 5-year survival rates for stages Ib, II, and III/IVa carcinoma were 93.5, 77.0, and 60.3%, respectively, and the 10-year survival rates were 90.9, 74.5, and 56.1%, respectively. Local control rates for stages Ib, II, and III/IVa carcinoma were 92.0, 79.4 and 64.2%, respectively. Eighty-two (5.5%) patients suffered grade III/IV or V (fatal) complications. A second cancer developed in 13 (0.87%) patients. Second cancers were observed most frequently in the rectum (five cases), colon (three cases), and uterine body (two cases). Long-term follow-up data revealed that our method of radiation therapy alone for locally advanced carcinoma of the uterine cervix is effective, with low incidences of late complications and second cancers.